trending Market Intelligence /marketintelligence/en/news-insights/trending/5h1F2phQjZRnhwSJFznW2w2 content esgSubNav
In This List

Alliance Pharma completes acquisition of TyraTech's head lice treatment

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Alliance Pharma completes acquisition of TyraTech's head lice treatment

Alliance Pharma plc completed its acquisition of the worldwide rights to TyraTech, Inc.'s Vamousse.

TyraTech's shareholders approved the deal on Dec. 27.

Vamousse assets comprise consumer healthcare products for preventing and treating human head lice.